Phase i trial of dasatinib and ixabepilone in patients with solid tumors

Investigational New Drugs

Volumn 31, Issue 1, 2013, Pages 92-98

  Herbolsheimer, P ^a   Kapoor, R ^a   Smith, K L ^a   Perry, D ^a   Verma, N ^a   Veytsman, I ^a   Jelinek, J ^a   Swain, S M ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Dasatinib; Ixabepilone; Phase 1

Indexed keywords

DASATINIB; IXABEPILONE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COHORT ANALYSIS; DEHYDRATION; DIARRHEA; DOSE LIMITING TOXICITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HUMAN; HUMAN CELL; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LIVER FUNCTION TEST; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PAIN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SOLID TUMOR; SYSTOLIC DYSFUNCTION; THORAX PAIN; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPOTHILONES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; TUBULIN MODULATORS;

EID: 84873095545     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9805-y     Document Type: Article

References (27)

1. Aleshin A, Finn RS (2010) SRC: A century of science brought to the clinic. Neoplasia 12(8):599-607
2. Tal J, Fujita DJ, Kawai S, Varmus HE, Bishop JM (1977) Purification of DNA complementary to the env gene of avian sarcoma virus and analysis of relationships among the env genes of avian leukosis-sarcoma viruses. J Virol 21(2):497-505
3. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70
4. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399-401
5. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47(27):6658-6661
6. Sprycel (dasatinib): package insert. Rev. ed. New York: Bristol-Myers Squibb, November 2007
7. Montero JC, Seoane S, Ocana A, Pandiella A (2011) Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 17(17):5546-5552
8. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH (2004) The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science 305(5685):866-869
9. Goodin S, Kane MP, Rubin EH (2004) Epothilones: Mechanism of action and biologic activity. J Clin Oncol 22(10):2015-2025
10. Ixempra (ixabepilone) kit for injection: package insert. Princeton, NJ: Bristol-Myers Squibb, 2009
11. Suter DM, Schaefer AW, Forscher P (2004) Microtubule dynamics are necessary for SRC family kinase-dependent growth cone steering. Curr Biol 14(13):1194-1199
12. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) Inhibition of Src tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10(7):2307-2318
13. Chen T, Pengetnze Y, Taylor CC (2005) Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther 4(2):217-224
14. Park BJ, Whichard ZL, Corey SJ (2012) Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lilnes - lessons for design of combination targeted therapy. Cancer Lett Feb1. [Epub ahead of print]
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
16. Xu XS, Zeng J, Mylott W, Arnold M, Waltrip J, Iacono L, Mariannino T, Stouffer B (2010) Liquid chromatography and tandem mass spectrometry for the quantitative determination of ixabepilone (BMS-247550, Ixempra) in human plasma: method validation, overcoming curve splitting issues and eliminating chromatographic interferences from degradants. J Chromatogr B Analyt Technol Biomed Life Sci 878(5-6):525-537
17. Furlong MT, Agrawal S, Hawthorne D, Lago M, Unger S, Krueger L, Stouffer B (2012) A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal 58:130-135
18. Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, Steinberg SM, Mannan N, Fojo T, Swain SM (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23(12):2726-2734
19. Denduluri N, Low JA, Lee JJ, Berman AW, Walshe JM, Vatas U, Chow CK, Steinberg SM, Yang SX, Swain SM (2007) Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 25(23):3421-3427
20. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN (2007) Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane and capecitabine. J Clin Oncol 25(23):3407-3414
21. Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25(23):3399-3406
22. Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improved tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26(19):3204-3212
23. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottman O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M (2007) Dasatinib indoces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109(8):3207-3213
24. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531-2541
25. Evans TR, Morgan JA, van den Abbeele AD et al. Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors (2005) J Clin Oncol 23(16S). Abstract 3034.
26. Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Chang J, Norton L, Hudis CA (2011) A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol 22(12):2575-2581
27. Araujo J, Gallick G, Trudel P, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180-086) (2009) Genitourinary Cancers Symposium. Abstract 177